These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 17237004)
1. [An update on recent developments in non-Hodgkin's lymphoma]. Bouabdallah K; Milpied N Bull Cancer; 2007 Jan; 94(1):43-52. PubMed ID: 17237004 [TBL] [Abstract][Full Text] [Related]
2. The therapeutic use of rituximab in non-Hodgkin's lymphoma. Marcus R; Hagenbeek A Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [TBL] [Abstract][Full Text] [Related]
4. Diffuse aggressive lymphoma. Fisher RI; Miller TP; O'Connor OA Hematology Am Soc Hematol Educ Program; 2004; ():221-36. PubMed ID: 15561685 [TBL] [Abstract][Full Text] [Related]
5. [Therapeutic management of central nervous system lymphomas in a single hematological institute]. Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012 [TBL] [Abstract][Full Text] [Related]
6. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M; Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042 [TBL] [Abstract][Full Text] [Related]
7. A Bayesian approach to a patient with a residual mass after treatment for non-Hodgkin's lymphoma of the thyroid. Bibb J; Hromas R; Rabinowitz I J Clin Oncol; 2005 Dec; 23(34):8911-3. PubMed ID: 16314654 [No Abstract] [Full Text] [Related]
8. [Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: study of 26 patients]. Moreno M; Sancho JM; Gardella S; Coll R; García O; Gallardo D; Ribera JM Med Clin (Barc); 2010 Jan; 134(2):72-5. PubMed ID: 19913261 [TBL] [Abstract][Full Text] [Related]
9. False-positive FDG-PET findings due to bone metastasis from prostate cancer in staging of non-Hodgkin's lymphoma. Inoue Y; Tamaki H; Yamagami T; Iwasaki H; Nakatsuka S; Soma T Eur J Haematol; 2007 Jul; 79(1):88-90. PubMed ID: 17532762 [No Abstract] [Full Text] [Related]
10. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Han HS; Escalón MP; Hsiao B; Serafini A; Lossos IS Ann Oncol; 2009 Feb; 20(2):309-18. PubMed ID: 18842613 [TBL] [Abstract][Full Text] [Related]
11. Immunochemotherapy: the new standard in aggressive non-Hodgkin's lymphoma in the elderly. Coiffier B Semin Oncol; 2003 Feb; 30(1 Suppl 2):21-7. PubMed ID: 12652461 [TBL] [Abstract][Full Text] [Related]
12. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Boye J; Elter T; Engert A Ann Oncol; 2003 Apr; 14(4):520-35. PubMed ID: 12649096 [TBL] [Abstract][Full Text] [Related]
14. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N; Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214 [TBL] [Abstract][Full Text] [Related]
15. Bendamustine-rituximab: a cost-utility analysis in first-line treatment of indolent non-Hodgkin's lymphoma in England and Wales. Dewilde S; Woods B; Castaigne JG; Parker C; Dunlop W J Med Econ; 2014 Feb; 17(2):111-24. PubMed ID: 24308372 [TBL] [Abstract][Full Text] [Related]
17. Early response assessment using 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Herrmann K; Wieder HA; Buck AK; Schöffel M; Krause BJ; Fend F; Schuster T; Meyer zum Büschenfelde C; Wester HJ; Duyster J; Peschel C; Schwaiger M; Dechow T Clin Cancer Res; 2007 Jun; 13(12):3552-8. PubMed ID: 17575218 [TBL] [Abstract][Full Text] [Related]
18. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail]. Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785 [TBL] [Abstract][Full Text] [Related]